Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2701 to 2715 of 8902 results

  1. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  2. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  3. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  4. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  5. Symptoms of peripheral arterial disease: ramipril (ESUOM45)

    Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

  6. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

  7. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

    Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

  8. Bile acid malabsorption: colesevelam (ESUOM22)

    Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

  9. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  10. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  11. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  12. Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

    Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

  13. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  14. External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

    Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

  15. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making